CDKN2A and lung cancer: CDK4/Cyclin D kinase constitutes an established biomarker in lung cancer, hyperactivity of which is associated with mutations in the p16INK4a-cyclin D-CDK4/6-pRb pathway 9, 11, 14, 53, 54.